Kanjinti’s Path To Market Complicated By GMP Issues, Reference Product Drift
Executive Summary
US FDA licensure of Amgen’s biosimilar to Herceptin was delayed by a complete response letter citing product manufacturing facility deficiencies; review documents discuss how drift in Genentech's reference product impacted the biosimilar program's analytical and clinical data.